DOCSLIB.ORG

TABLE VI.- Classification Obtained by Linear Discriminant Analysis on Carcinogenic Activity Study : (Compounds Cataloged on Merck Index)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
TABLE VI.- Classification Obtained by Linear Discriminant Analysis on Carcinogenic Activity Study : (Compounds Cataloged on Merck Index) TABLE VI.- Classification obtained by linear discriminant analysis on carcinogenic activity study : (compounds cataloged on Merck Index). C = high expectancy of being carcinogenic (>90%) ; PC = probable carcinogenic activity (between 70% and 90%) ; I = high expectancy of being non carcinogenic(>90%); PI = probable non carcinogenic activity (between 70% and 90%); U = non classified. 3,4-diaminopyridine 2.34 C Compound DFcarc Class. 3,4-dichloroaniline 2.13 C 3,5-dibromo-l-tyrosine -0.54 U 1,1,2-trichloroethane 5.30 C 3,5-dibromosalicylaldehyde -0.27 U 1,1-diphenylhydrazine 4.19 C 3-carene 2.30 C 1,2,3-trichlorobenzene 3.86 C 3-ethylpyridine 1.85 PC 1,2-dianilinoethane 1.74 PC 3-methyl-2-butanol 3.66 C 1,2-naphthoquinone 1.07 PC 3-methylcholanthrene 10.30 U 1,3,5-trichlorobenzene 6.67 C 3-pentanol 5.00 C 1,3-butadiene 8.12 C 4-ethylpyridine 2.87 C 1,3-dichloroacetone 5.65 C 4-nitrosophenol 3.98 C 1,3-diphenylguanidine 1.21 PC 4-phenylsemicarbazide -0.17 U 1,4-naphthoquinone 4.37 C 5-bromouracil -0.42 U 16-epiestriol 3.19 C 5-diazouracil 3.71 C 1-butene 5.06 C 5-methoxytryptamine 1.99 PC 1-dodecanol 1.87 PC 5-nitrobarbituric 1.51 PC 1-fluoro-2,4-dinitrobenzene 0.19 U 6-azauridine -3.15 I 1h-1,2,4-triazole 3.75 C 8-azaguanine 0.30 U 1-naphthoic,acid 0.21 U 9,10-dibromoanthracene 8.02 C 1-naphthol 1.65 PC Acebutolol -5.12 I 1-nitropropane 4.63 C Acecainide -3.39 I 1-nitroso-2-naphthol 1.95 PC Aceclofenac -3.27 I 1-pentene 4.41 C Acedapsone -0.13 U 1-phenyl-3-pyrazolidinone -0.91 U Acediasulfone -1.23 PI 2,4,6-tribromophenol 2.77 C Aceglatone -0.27 U 2,4,6-trichloroanisole 2.40 C Aceglutamide -2.95 I 2,4,6-trichlorophenol 2.81 C Acenaphthene 13.62 U 2,4,6-trinitrotoluene 0.06 U Acenocoumarol -3.59 I 2,4-dichlorophenol 1.45 PC Aceperone -4.02 I 2,4-difluoroaniline 2.01 C Acesulfame 1.25 PC 2,4-dinitroaniline -1.69 PI Acetaldehyde 6.00 C 2,4-dinitrophenol -0.52 U Acetaldoxime 5.76 C 2,4-dinitrophenylhydrazine -0.99 U Acetamide 2.91 C 2,5-dinitrophenol 0.46 U Acetanilide 0.32 U 2,6-diaminopurine 2.68 C Acetazolamide -1.05 PI 2,6-dichlorophenol 3.19 C Acetiamine -4.01 I 2,6-dinitrophenol 2.20 C Acetohexamide -2.87 I 2,6-lutidine 4.63 C Acetonitrile 6.00 C 2-amino-4-picoline 2.34 C Acetophenazine -6.25 I 2-aminobenzothiazole 8.18 C Acetophenone 2.65 C 2-aminothiazole 3.28 C Acetylcysteine -2.20 I 2-heptanone 1.47 PC Acetylene 10.52 U 2-mercaptobenzothiazole 12.33 U Acifran -1.74 PI 2-methyl-1-butanol 2.99 C Acipimox -0.01 U 2-methyl-3-butyn-2-ol 3.66 C Acitretin -1.82 PI 2-methylanthraquinone 0.10 U Acrivastine -3.89 I 2-naphthalenethiol 2.99 C Acrylamide 4.08 C 2-naphthol 2.07 C Actinoquinol -2.41 I 2-nitropropane 5.31 C Acyclovir -1.77 PI 2-octanol 1.34 PC Adamantane 8.54 C 2-pentanol 2.97 C Adenine -3.75 I 2-pentene 4.41 C Adrafinil 0.30 U 2-phenoxyethanol 1.85 PC Afloqualone -3.59 I 2-thiouracil 1.70 PC A-furildioxime 3.36 C Aklomide 0.61 U Amygdalin -7.09 I Alacepril -4.78 I Amylbenzene 1.71 PC Alantolactone -0.27 U Anagestone 3.32 C Albendazole 0.31 U Anagrelide 1.13 PC Albuterol -4.63 I Ancitabine -1.48 PI Albutoin 2.22 C Androsterone 5.27 C Alclofenac -0.88 U Aniline 4.67 C Alclometasone -1.53 PI Aniracetam -0.73 U Aldicarb 1.09 PC Anisindione 3.41 C Aldosterone 2.30 C Anisole 3.38 C Aldrin 7.85 C Antazoline -1.24 PI Alexidine -5.29 I Anthracene 9.26 C Alfaprostol -2.21 I Anthralin 0.15 U Algestone 2.75 C Antipyrine -1.28 PI Alinidine -2.54 I Antrafenine -3.66 I Alizapride -2.96 I Apalcillin -6.71 I Allantoin -2.39 I A-phenylglycine 0.54 U Alloclamide -3.78 I Apholate -5.35 I Allylamine 5.06 C Apigenin -2.01 I Allylestrenol 5.82 C Apomorphine -4.65 I Alminoprofen -2.38 I Apramycin -8.26 I Aloin -9.51 I Arabinose -0.93 U Alphaprodine -5.18 I Arbekacin -8.25 I Alpidem -1.63 PI Arecaidine -1.61 PI Altrenogest 1.69 PC Arginine -1.63 PI Alverine 1.99 PC Arotinolol -1.61 PI Amanozine -1.14 PI Artemisinin -5.66 I Amantadine 4.90 C Aspartame -3.31 I Ambazone 8.51 C Aspidospermine 10.50 U Ambucetamide -2.40 I Aspoxicillin -8.36 I Ambuside -2.65 I Astemizole -1.82 PI Amcinonide -1.39 PI Atenolol -1.95 PI Amdinocillin -1.80 PI Atranorin -5.13 I Ametryn -6.60 I Atropine -2.35 I Amfenac -1.31 PI Azacitidine -4.24 I Amikacin -10.66 U Azacosterol 4.23 C Aminoglutethimide -3.06 I Azacyclonol -1.92 PI Aminoguanidine 3.25 C Azanidazole -1.03 PI Aminometradine -2.47 I Azaperone -1.77 PI Aminopentamide -3.23 I Azatadine -4.85 I Aminopromazine -4.78 I Azelastine -4.27 I Aminopterin -4.20 I Azidocillin -3.24 I Aminopyrine -3.06 I Azintamide -0.80 U Aminoquinuride 1.26 PC Azlocillin -8.47 I Aminorex 2.98 C Azobenzene 9.79 C Amiodarone -0.38 U Azomycin -4.29 I Amitriptyline -1.51 PI Azosemide -3.66 I Amixetrine -2.13 I Aztreonam -3.77 I Amlexanox -2.62 I Azulene 5.78 C Amlodipine -6.88 I Azure,b -2.33 I Amoproxan -3.23 I Azure,c -0.26 U Amorolfine -2.15 I Bacampicillin -3.67 I Amoscanate 8.23 C Baclofen -0.58 U Amotriphene -1.85 PI Bambuterol -4.64 I Amoxapine -3.66 I Bamethan -1.90 PI Amperozide -1.94 PI Bamifylline -7.03 I Amphecloral 2.48 C Bamipine -3.30 I Amphenidone -0.95 U Barban -0.15 U Amphetamine 2.10 C Befunolol -0.83 U Amphotalide 1.77 PC Bemegride -0.10 U Ampicillin -4.35 I Benapryzine -2.16 I Ampiroxicam -5.29 I Bencyclane -1.19 PI Amsacrine -1.21 PI Bendazac 0.26 U Bendiocarb -1.95 PI Bromacil -3.36 I Bendroflumethiazide -4.46 I Bromazepam -2.32 I Benfluorex -1.82 PI Bromfenac -1.18 PI Benomyl -3.67 I Bromindione 3.84 C Benoxaprofen 1.02 PC Bromisovalum -0.37 U Benperidol -0.05 U Bromobenzene 4.67 C Benserazide -4.68 I Bromodiphenhydramine -0.94 U Benzaldehyde 4.04 C Bromoform 8.37 C Benzamide 3.09 C Bromophos 5.80 C Benzanilide 0.31 U Bromopride -4.42 I Benzbromarone -0.22 U Bromperidol -1.57 PI Benzene 11.18 U Broxyquinoline 0.59 U Benzestrol -3.23 I Brucine 17.52 U Benzetimide -5.48 I Bucillamine -2.29 I Benzil 4.05 C Bucladesine -0.46 U Benzimidazole 5.05 C Buclizine -3.06 I Benznidazole -1.51 PI Bucolome -5.17 I Benzoctamine -2.64 I Bucumolol -3.32 I Benzodepa -3.27 I Budesonide -0.68 U Benzofuran 5.80 C Budipine -1.33 PI Benzoic,acid 2.53 C Budralazine 0.28 U Benzonatate 2.66 C Bufeniode -3.40 I Benzonitrile 3.69 C Bufetolol -3.37 I Benzophenone 5.09 C Bufuralol -0.52 U Benzothiazole 9.43 C Bunamidine -1.50 PI Benzoxiquine 1.15 PC Bupirimate -6.66 I Benzoyl,chloride 3.11 C Bupivacaine -4.66 I Benzoylecgonine -4.02 I Bupranolol -2.85 I Benzoylpas -1.99 PI Buprenorphine -1.40 PI Benzphetamine -1.31 PI Buramate -0.49 U Benzpiperylon -4.26 I Buspirone -2.66 I Benzyl,alcohol 3.32 C Butacaine 0.14 U Benzyl,cinnamate 0.84 U Butachlor -4.11 I Benzyl,ether 5.19 C Butalamine -1.15 PI Benzylamine 3.88 C Butamisole -1.84 PI Berbine -2.67 I Butanilicaine -3.95 I Betahistine -0.97 U Butaperazine -5.62 I Betamethasone -2.79 I Butaverine -3.42 I Beta-sitosterol 6.79 C Butethamine -0.01 U Betazole 1.47 PC Buthiazide -5.27 I Bethanidine -0.10 U Butibufen -1.46 PI Bevantolol -3.26 I Butoconazole -2.60 I Bezafibrate -1.65 PI Butofilolol -4.21 I Bezitramide -3.43 I Butorphanol -5.90 I Bialamicol -3.90 I Butralin -5.14 I Bibenzyl 5.49 C Butriptyline -2.26 I Bicuculline -0.38 U Butyraldehyde 4.41 C Bifenox -1.61 PI Butyronitrile 4.41 C Bifluranol -4.34 I Cadralazine -5.91 I Bifonazole 0.06 U Caffeine -1.70 PI Binedaline 0.56 U Calcifediol 7.15 C Binifibrate -0.98 U Calcitriol 6.30 C Bioresmethrin 0.05 U Camazepam -2.98 I Biotin -4.18 I Cambendazole 0.98 U Biperiden -4.45 I Camostat -1.42 PI Biphenamine -1.41 PI Camphor 1.49 PC Bisoprolol -1.56 PI Camptothecin 0.29 U Bitolterol -4.17 I Capuride -2.66 I Bitoscanate 20.24 U Carbamazepine -0.46 U Bolasterone 3.72 C Carbazole 10.51 U Boldenone 7.89 C Carbendazim 1.46 PC Bopindolol 0.22 U Carbetapentane -1.14 PI Brodimoprim -1.41 PI Carbinoxamine -2.11 I Carbiphene -4.25 I Chloropyramine -3.38 I Carbocloral -0.78 U Chlorothen -4.40 I Carbocysteine -0.73 U Chlorothiazide -0.79 U Carbofuran -0.93 U Chlorozotocin -4.78 I Carboprost -3.39 I Chlorphenesin 0.29 U Carboquone -7.09 I Chlorphenoxamine -2.16 I Carbubarb -4.06 I Chlorphentermine 1.31 PC Carbutamide -2.40 I Chlorpromazine -4.88 I Carbuterol -5.61 I Chlorprothixene -3.36 I Carminic,acid -12.79 U Chlorquinaldol -1.19 PI Carmofur -2.82 I Chlortetracycline -10.91 U Caroverine -3.53 I Cholesterol 7.11 C Carphenazine -6.18 I Chrysene 6.57 C Carpipramine -4.77 I Chrysophanic,acid -3.69 I Carprofen 3.90 C Ciclonicate -1.37 PI Carsalam 0.07 U Cilastatin -3.88 I Carvedilol 3.35 C Cilazapril -7.41 I Carzenide 0.67 U Cilostazol -3.99 I Castanospermine 3.66 C Cimaterol -3.57 I Cathinone 1.57 PC Cimetidine -1.90 PI Cefaclor -3.99 I Cinchonine -2.81 I Cefamandole -5.85 I Cinchophen -0.62 U Cefatrizine -4.84 I Cinitapride -4.55 I Cefazedone -4.47 I Cinnamedrine -2.13 I Cefazolin -5.38 I Cinnamyl,alcohol 2.16 C Cefixime -4.53 I Cinnarizine -1.95 PI Cefminox -6.83 I Cinnoline 2.61 C Cefotaxime -4.19 I Cinoxacin -2.78 I Cefoxitin -5.69 I Cinoxate 0.28 U Cefpiramide -8.47 I Cinromide -1.22 PI Cefroxadine -4.33 I Ciprofibrate -0.78 U Cefteram -4.68 I Ciprofloxacin -7.14 I Ceftizoxime -3.76 I Cisapride -4.61 I Ceftriaxone -4.77 I Citiolone -1.75 PI Cefuroxime -4.26 I Citrulline -1.57 PI Cephalothin -5.04 I Clanobutin -2.56 I Cephradine -5.30 I Clebopride -4.24 I Cetiedil -2.77 I Clemastine -2.81 I Cetirizine -3.67 I Clemizole -1.12 PI Cetraxate -0.46 U Clenbuterol -2.05 I Ches -0.50 U Clindamycin -8.06 I Chlophedianol -4.53 I Clinofibrate -4.04 I Chloramben -0.69 U Clioxanide -3.70 I Chlorambucil -1.29 PI Clobenzepam -6.54 I Chloramphenicol -3.02 I Clobenzorex -1.79 PI Chlorbenzoxamine -3.55 I Clobenztropine -1.75 PI Chlorbetamide -2.53 I Clobetasol -1.49 PI Chlorcyclizine
Load more

Recommended publications
  • Journal of Pharmacology and Experimental Therapeutics
    Journal of Pharmacology and Experimental Therapeutics Molecular Determinants of Ligand Selectivity for the Human Multidrug And Toxin Extrusion Proteins, MATE1 and MATE-2K Bethzaida Astorga, Sean Ekins, Mark Morales and Stephen H Wright Department of Physiology, University of Arizona, Tucson, AZ 85724, USA (B.A., M.M., and S.H.W.) Collaborations in Chemistry, 5616 Hilltop Needmore Road, Fuquay-Varina NC 27526, USA (S.E.) Supplemental Table 1. Compounds selected by the common features pharmacophore after searching a database of 2690 FDA approved compounds (www.collaborativedrug.com). FitValue Common Name Indication 3.93897 PYRIMETHAMINE Antimalarial 3.3167 naloxone Antidote Naloxone Hydrochloride 3.27622 DEXMEDETOMIDINE Anxiolytic 3.2407 Chlordantoin Antifungal 3.1776 NALORPHINE Antidote Nalorphine Hydrochloride 3.15108 Perfosfamide Antineoplastic 3.11759 Cinchonidine Sulfate Antimalarial Cinchonidine 3.10352 Cinchonine Sulfate Antimalarial Cinchonine 3.07469 METHOHEXITAL Anesthetic 3.06799 PROGUANIL Antimalarial PROGUANIL HYDROCHLORIDE 100MG 3.05018 TOPIRAMATE Anticonvulsant 3.04366 MIDODRINE Antihypotensive Midodrine Hydrochloride 2.98558 Chlorbetamide Antiamebic 2.98463 TRIMETHOPRIM Antibiotic Antibacterial 2.98457 ZILEUTON Antiinflammatory 2.94205 AMINOMETRADINE Diuretic 2.89284 SCOPOLAMINE Antispasmodic ScopolamineHydrobromide 2.88791 ARTICAINE Anesthetic 2.84534 RITODRINE Tocolytic 2.82357 MITOBRONITOL Antineoplastic Mitolactol 2.81033 LORAZEPAM Anxiolytic 2.74943 ETHOHEXADIOL Insecticide 2.64902 METHOXAMINE Antihypotensive Methoxamine
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
    US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • The Concise Guide to Pharmacology 2019/20
    Edinburgh Research Explorer THE CONCISE GUIDE TO PHARMACOLOGY 2019/20 Citation for published version: Cgtp Collaborators 2019, 'THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Transporters', British Journal of Pharmacology, vol. 176 Suppl 1, pp. S397-S493. https://doi.org/10.1111/bph.14753 Digital Object Identifier (DOI): 10.1111/bph.14753 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: British Journal of Pharmacology General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 28. Sep. 2021 S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: Transporters. British Journal of Pharmacology (2019) 176, S397–S493 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Transporters Stephen PH Alexander1 , Eamonn Kelly2, Alistair Mathie3 ,JohnAPeters4 , Emma L Veale3 , Jane F Armstrong5 , Elena Faccenda5 ,SimonDHarding5 ,AdamJPawson5 , Joanna L
    [Show full text]
  • Part I Biopharmaceuticals
    1 Part I Biopharmaceuticals Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 3 1 Analogs and Antagonists of Male Sex Hormones Robert W. Brueggemeier The Ohio State University, Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Columbus, Ohio 43210, USA 1Introduction6 2 Historical 6 3 Endogenous Male Sex Hormones 7 3.1 Occurrence and Physiological Roles 7 3.2 Biosynthesis 8 3.3 Absorption and Distribution 12 3.4 Metabolism 13 3.4.1 Reductive Metabolism 14 3.4.2 Oxidative Metabolism 17 3.5 Mechanism of Action 19 4 Synthetic Androgens 24 4.1 Current Drugs on the Market 24 4.2 Therapeutic Uses and Bioassays 25 4.3 Structure–Activity Relationships for Steroidal Androgens 26 4.3.1 Early Modifications 26 4.3.2 Methylated Derivatives 26 4.3.3 Ester Derivatives 27 4.3.4 Halo Derivatives 27 4.3.5 Other Androgen Derivatives 28 4.3.6 Summary of Structure–Activity Relationships of Steroidal Androgens 28 4.4 Nonsteroidal Androgens, Selective Androgen Receptor Modulators (SARMs) 30 4.5 Absorption, Distribution, and Metabolism 31 4.6 Toxicities 32 Translational Medicine: Molecular Pharmacology and Drug Discovery First Edition. Edited by Robert A. Meyers. © 2018 Wiley-VCH Verlag GmbH & Co. KGaA. Published 2018 by Wiley-VCH Verlag GmbH & Co. KGaA. 4 Analogs and Antagonists of Male Sex Hormones 5 Anabolic Agents 32 5.1 Current Drugs on the Market 32 5.2 Therapeutic Uses and Bioassays
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Letter Bill 1..143
    Public Act 097-0334 HB2917 Enrolled LRB097 06471 RLC 50343 b AN ACT concerning controlled substances. Be it enacted by the People of the State of Illinois, represented in the General Assembly: Section 5. The Illinois Controlled Substances Act is amended by changing Sections 100, 102, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 301, 302, 303, 303.05, 303.1, 304, 305, 306, 309, 312, 313, 316, 317, 318, 319, 320, 405, 405.1, 406, 408, 410, 411.2, 413, 501, 501.1, 503, 504, 505, 507, and 510 and by adding Sections 311.5, 314.5, and 507.2 as follows: (720 ILCS 570/100) (from Ch. 56 1/2, par. 1100) Sec. 100. Legislative intent. It is the intent of the General Assembly, recognizing the rising incidence in the abuse of drugs and other dangerous substances and its resultant damage to the peace, health, and welfare of the citizens of Illinois, to provide a system of control over the distribution and use of controlled substances which will more effectively: (1) limit access of such substances only to those persons who have demonstrated an appropriate sense of responsibility and have a lawful and legitimate reason to possess them; (2) deter the unlawful and destructive abuse of controlled substances; (3) penalize most heavily the illicit traffickers or profiteers of controlled substances, who propagate and perpetuate the Public Act 097-0334 HB2917 Enrolled LRB097 06471 RLC 50343 b abuse of such substances with reckless disregard for its consumptive consequences upon every element of society; (4) acknowledge the functional and consequential differences between the various types of controlled substances and provide for correspondingly different degrees of control over each of the various types; (5) unify where feasible and codify the efforts of this State to conform with the regulatory systems of the Federal government and other states to establish national coordination of efforts to control the abuse of controlled substances; and (6) provide law enforcement authorities with the necessary resources to make this system efficacious.
    [Show full text]
  • Preparation and Chiral HPLC Separation of the Enantiomeric Forms of Natural Prostaglandins
    Article Preparation and Chiral HPLC Separation of the Enantiomeric Forms of Natural Prostaglandins Márton Enesei 1,2,László Takács 2, Enik˝oTormási 3, Adrienn Tóthné Rácz 3, Zita Róka 3, Mihály Kádár 3 and Zsuzsanna Kardos 2,* 1 Department of Organic Chemistry and Technology, Budapest University of Technology and Economics, M˝uegyetemrakpart 3, 1111 Budapest, Hungary; [email protected] 2 CHINOIN, a member of Sanofi Group, PG Development, Tó utca 1-5, 1045 Budapest, Hungary; laszlo.takacs@sanofi.com 3 CHINOIN, a member of Sanofi Group, PG Analytics, Tó utca 1-5, 1045 Budapest, Hungary; robertne.tormasi@sanofi.com (E.T.); adrienn.tothneracz@sanofi.com (A.T.R.); zita.roka@sanofi.com (Z.R.); mihaly.kadar@sanofi.com (M.K.) * Correspondence: zsuzsanna.kardos@sanofi.com Received: 15 June 2020; Accepted: 10 August 2020; Published: 18 August 2020 Abstract: Four enantiomeric forms of natural prostaglandins, ent-PGF α (( )-1), ent-PGE ((+)-2) 2 − 2 ent-PGF α (( )-3), and ent-PGE ((+)-4) have been synthetized in gram scale by Corey synthesis used 1 − 1 in the prostaglandin plants of CHINOIN, Budapest. Chiral HPLC methods have been developed to separate the enantiomeric pairs. Enantiomers of natural prostaglandins can be used as analytical standards to verify the enantiopurity of synthetic prostaglandins, or as biomarkers to study oxidation processes in vivo. Keywords: preparation; ent-PGF2α; ent-PGF1α; ent-PGE2; ent-PGE1; chiral HPLC; enantiomeric separation; mirror images; enantiopurity 1. Introduction Interest in the field of prostaglandins has been steadily growing since the basic work of Bergström Samuelsson, and Vane [1–3]. Their discoveries revealed the structure, the enzyme-controlled biochemical synthesis from arachidonic acid, and the main physiological effects of prostaglandins as well as their related substances.
    [Show full text]
  • Food and Drug Administration, HHS § 310.201
    Food and Drug Administration, HHS § 310.201 (d) Prescription legend not allowed on (v) The preparation is labeled with exempted drugs. The use of the prescrip- adequate directions for use in minor tion caution statement quoted in sec- conditions as a simple analgesic. tion 503(b) (4) of the act, in the labeling (vi) The dosages of N-acetyl-p-amino- of a drug exempted under the provi- phenol recommended or suggested in sions of this section, constitutes mis- the labeling do not exceed: For adults, branding. Any other statement or sug- 0.65 gram (10 grains) per dose or 2.6 gestion in the labeling of a drug ex- grams (40 grains) per 24-hour period: for empted under this section, that such children 6 to 12 years of age, one-half of drug is limited to prescription use, the maximum adult dose or dosage; for may constitute misbranding. children 3 to 6 years of age, one-fifth of (e) Prescription-exemption procedure of the maximum adult dose or dosage. OTC drug review. A drug limited to pre- (vii) The labeling bears, in juxtaposi- scription use under section 503(b)(1)(B) tion with the dosage recommendations, of the act may also be exempted from a clear warning statement against ad- prescription-dispensing requirements ministration of the drug to children by the procedure set forth in § 330.13 of under 3 years of age and against use of this chapter. the drug for more than 10 days, unless such uses are directed by a physician. [39 FR 11680, Mar.
    [Show full text]